EYEPOINT PHARMACEUTICALS ($EYPT) posted quarterly earnings results on Wednesday, March 5th. The company reported earnings of -$0.64 per share, missing estimates of -$0.51 by $0.13. The company also reported revenue of $11,590,000, beating estimates of $11,313,840 by $276,160.
You can see Quiver Quantitative's $EYPT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
EYEPOINT PHARMACEUTICALS Hedge Fund Activity
We have seen 88 institutional investors add shares of EYEPOINT PHARMACEUTICALS stock to their portfolio, and 78 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. added 3,181,818 shares (+inf%) to their portfolio in Q4 2024, for an estimated $23,704,544
- TCG CROSSOVER MANAGEMENT, LLC added 2,650,000 shares (+287.3%) to their portfolio in Q4 2024, for an estimated $19,742,500
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,958,580 shares (+51.7%) to their portfolio in Q4 2024, for an estimated $14,591,421
- FEDERATED HERMES, INC. added 1,783,765 shares (+92.7%) to their portfolio in Q4 2024, for an estimated $13,289,049
- SUVRETTA CAPITAL MANAGEMENT, LLC added 1,607,268 shares (+31.1%) to their portfolio in Q4 2024, for an estimated $11,974,146
- BLACKROCK, INC. added 1,126,217 shares (+27.1%) to their portfolio in Q4 2024, for an estimated $8,390,316
- OCTAGON CAPITAL ADVISORS LP removed 1,093,503 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $8,146,597
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
